Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITIS-PUK
NCT07550296Phase 2Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Metabolic Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of recombinant human prourokinase in ischemic stroke (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Rate of vessel recanalization at 24 hours. Started May 2026; status: recruiting.
02
Drugs
recombinant human prourokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07550296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550296.